AF monitoring and stroke: XPECT & REVEAL LINQ

Helmut Pürerfellner, Linz, Austria









EHRA POSITION PAPER

Indications for the use of diagnostic implantable and external ECG loop recorders

Task Force members: Michele Brignole (Chairperson), Lavagna, Italy; Panos Vardas (Co-chairperson), Herakleion, Greece; Ellen Hoffman, Munich, Germany; Heikki Huikuri, Oulu, Finland; Angel Moya, Barcelona, Spain; Renato Ricci, Rome, Italy; Neil Sulke, Eastbourne, UK; Wouter Wieling, Amsterdam, The Netherlands

EHRA Scientific Documents Committee: Angelo Auricchio (Chairperson), Lugano, Switzerland; Gregory Y.H. Lip, Birmingham, UK; Jesus Almendral, Madrid, Spain; Paulus Kirchhof, Muenster, Germany; Etienne Aliot, Nancy, France; Maurizio Gasparini, Milan, Italy; Frieder Braunschweig, Stockholm, Sweden

Document Reviewers: Gregory Y.H. Lip, Birmingham, UK; Jesus Almendral, Madrid, Spain; Paulus Kirchhof, Muenster, Germany; Gian Luca Botto, Como, Italy



Part II: Non-established indications

3. Atrial fibrillation: therapy guided by loop recorder observations

Key points

- There is a poor correlation of symptoms with atrial fibrillation (AF), especially after rhythm control therapy is started, which makes subjective evaluation of the effect of any therapy unreliable
- There are two main potential reasons for accurate arrhythmia monitoring: in clinical practice to determine the efficacy of rhythm control therapy; in rhythm control trials when freedom from AF is the outcome parameter
- Owing to the unpredictable nature of recurrences, AF is significantly underdetected by intermittent monitoring systems
- Continuous monitoring by implantable devices further increases the detection of AF, but it is hampered by misdetections and artefacts.
- Technological improvements are required for significant reduction of maldetection. Manual analysis can improve diagnostic yield if stored electrograms are provided. The results of some on-going studies with new generation devices are awaited
- The clinical relevance of Loop Recorders to guide medical and device therapy has yet to be demonstrated



Circ Arrhythm Electrophysiol 2010;3:141-47

Performance of a New Leadless Implantable Cardiac Monitor in Detecting and Quantifying Atrial Fibrillation Results of the XPECT Trial

Gerhard Hindricks, MD, PhD; Evgueny Pokushalov, MD; Lubos Urban, MD; Milos Taborsky, MD, PhD; Karl-Heinz Kuck, MD, PhD; Dmitry Lebedev, MD, PhD; Guido Rieger, MD; Helmut Pürerfellner, MD; on behalf of the XPECT Trial Investigators



Reveal XT versus LINQ

5

EUROPEAN

ASSOCIATION

A Registered Branch of the ESC

Heart Rhythm EUROPEAN

SOCIETY OF

CARDIOLOGY®



Parameter	Reveal XT	Reveal LINQ [™]	
Longevity	3 years	3 years	
Electrode Spacing (inside-to-inside)	41 mm	38 mm	
Volume	9 сс	1.18 cc	
Mass	15 g	~2.5 g	
Episode Storage	49 min	57 min	
Patient Symptom Mark	Patient Assistant	Patient Assistant	
Cardiac Compass	Same	Same	
MRI Compatibility	MR Conditional	MR Conditional	
Clinician Notification	No	Nightly Transmission / CareAlerts	
Bi-Directional Telemetry	В	В	
Detection Algorithms	Full View	Full View + P-wave detection	
CareLink®	Yes	Yes New CL Full reports, online episode viewer, online trends viewer, episode rollup since implant, 31-day summary report, CareAler event reports, FullView zoom capability	
Wireless Telemetry	No	1-Way, Transmit Only	

www.escardio.org/EHRA

XPECT



Figure 3. AF burden measured by the ICM compared with AF burden calculated from the core laboratory–annotated Holter recording for all patients (r indicates Pearson correlation coefficient).

EUROPEAN Heart Rhythm

ASSOCIATION

SOCIETY OF

CARDIOLOGY



XPECT



Figure 4. AF episode detection sensitivity (left) and PPV (right), depending on episode duration. Episodes longer than the minimum duration are included in the analysis for each result. Bars denote confidence intervals.



Causes for Inappropriate AF Detection

- Over-sensing due to noise
- Bigeminy and trigeminy
- Frequent ectopy with irregular coupling interval
- Sick sinus: brady-tachy syndrome
- Sinus tachycardia with RR variability
- Under-sensing due to small amplitude or wide R-waves
- T-wave over-sensing or p-waves oversensing





Goal for AF detection in Reveal LinQ

Reduce episode review burden

- Algorithm enhancements in Reveal LinQ
- Nominal programming based on patient type
- Enhanced episode storage scheme

Preserve AF burden accuracy

Preserve Sensitivity to AF detection



P-SENSE: *P-wave Averaging*



P-SENSE: *P-wave feature extraction*

Morphology of Averaged ECG is used to identify

- Presence of P-wave
- Absence of atrial flutter waves
- Absence of baseline noise



P-SENSE: Modify AF evidence





AF detection in Reveal LinQ: *Programming options*





Optimizing AF Detection for Patient Type *Reduce burden of episode review*

Reason for Monitoring	Parameters			
	AF Detection Threshold	Ectopy Rejection	Episode Storage Threshold	
Syncope	Least	Aggressive	Longest Episode Only	AF detection
Seizures	Least	Aggressive	≥ 10 min	Thee to have
Ventricular Tachycardia	Least	Aggressive	≥ 10 min	
Palpitations	Less	Aggressive	≥ 6 min	Does patient
Suspected AF	Less	Aggressive	≥ 6 min	Have AF !
Cryptogenic Stroke	Balanced	Aggressive	All	
AF Ablation	Balanced	Nominal	All	Does patient
AF Management	Balanced	Nominal	All	have AF ? How much AF ?
Other	Less	Aggressive	≥ 10 min	



Heart Rhythm 2014;11:1575-1583

P-wave evidence as a method for improving algorithm to detect atrial fibrillation in insertable cardiac monitors



Helmut Pürerfellner, MD, FHRS,^{*} Evgeny Pokushalov, MD,[†] Shantanu Sarkar, PhD,[‡] Jodi Koehler, MS,[‡] Ren Zhou, MS,[‡] Lubos Urban, MD,[§] Gerhard Hindricks, MD, FHRS

From the ^{*}Department of Cardiology, Krankenhaus der Elisabethinen, Linz, Austria, [†]State Research Institute of Circulation Pathology, Novosibirsk, Russia, [‡]Medtronic Incorporated, Mounds View, Minnesota, [§]The National Institute of Cardiovascular Diseases, Bratislava, Slovakia, and [¶]Heart Center, University of Leipzig, Leipzig, Germany.



P-SENSE Performance summary

- False episodes reduced by 46% with 2% reduction in true episodes
- False duration reduced by 55% with 0.1% reduction in true duration
- Detected 97.8% of total AF duration
- Detected 99.3% of total sinus or non-AF rhythm duration
- Detected 85% (90% patient average) of all AF episodes ≥2 minutes
- 55% (78% patient average) of detected episodes had AF
 - 95% of detected episodes >1 hour had AF
 - 14% of patients had false detects
 - 7% of patients with only false detects
 - 3 patients account for 70% of false detects





www.escardio.org/EHRA

EUROPEAN Heart Rhythm ASSOCIATION Absociation

Reveal XT versus LINQ



Parameter	Reveal XT	Reveal LINQ [™]	
Longevity	3 years	3 years	
Electrode Spacing (inside-to-inside)	41 mm	38 mm	
Volume	9 сс	1.18 cc	
Mass	15 g	~2.5 g	
Episode Storage	49 min	57 min	
Patient Symptom Mark	Patient Assistant	Patient Assistant	
Cardiac Compass	Same	Same	
MRI Compatibility	MR Conditional	MR Conditional	
Clinician Notification	No	Nightly Transmission / CareAlerts	
Bi-Directional Telemetry	В	В	
Detection Algorithms	Full View	Full View + P-wave detection	
CareLink®	Yes	Yes New CL Full reports, online episode viewer, online trends viewer, episode rollup since implant, 31-day summary report, CareAlert event reports, FullView zoom capability	
Wireless Telemetry	No	1-Way, Transmit Only	

www.escardio.org/EHRA

19

EUROPEAN

ASSOCIATION

A Registered Branch of the ESC

Heart Rhythm EUROPEAN

SOCIETY OF

CARDIOLOGY®

LINQ[™] System Components





Heart Rhythm 2015 (in press)

ACCEPTED MANUSCRIPT

Miniaturized Reveal LINQTM Insertable Cardiac Monitoring (ICM) System: First in Man Experience

Pürerfellner, Helmut, MD, FHRS¹, Sanders, Prashanthan, MBBS, PhD, FHRS², Pokushalov, Evgeny, MD³, Di Bacco, Marco, PharmD⁴, Bergemann, Tracy, PhD⁵, Dekker, Lukas R.C., MD, PhD⁶ for the Reveal LINQTM Usability Study Investigators



1

Insertion Procedure: Insertion

Procedure Location:

- Cath Lab: n=25 (83.3%)
- Clean Room: n=5 (16.7%)

Insertion Location:



Primary Indication	Implanted Subjects (n=30)
Syncope	19 (63.3%)
Palpitations	3 (10.0%)
Seizures	0 (0.0%)
Suspected AF	2 (6.7%)
AF Ablation Monitoring	2 (6.7%)
AF Management	2 (6.7%)
Cryptogenic Stroke	1 (3.3%)
Ventricular Tachycardia	0 (0.0%)
Other	1 (3.3%)



www.escardio.org/EHRA

Results

- 100% (n=30) implant success for Phase I
- Successful transmissions in 79,5%
- R-wave amplitude ≥200µV at implant for 96.7% of subjects
- High physician and patient acceptance
- No significant migration
- No reportable system or procedure adverse events

Note: The Reveal LINQ System has received CE Mark and TGA Approval and is Pending FDA 510K Clearance



Reveal LINQ





www.escardio.org/EHRA

AF diagnosis and monitoring: Clinical Applications

Secondary stroke prevention (post cryptogenic stroke)

- Sinha AM et al Am Heart J. 2010;160(1):36-41.
- Ritter MA et al Stroke. 2013;44(5):1449-52.
- Etgen T et al. Stroke. 2013;44(7):2007-9.

Pre and post PV ablation

- Pokuslalov E et al. J Cardiovasc Electrophysiol. 2011;22(4):369-75.
- Verma A et al. JAMA Intern Med. 2013;173(2):149-56.
- Kapa S et al. J Cardiovasc Electrophysiol. 2013;24(8):875-81.

Post surgical AF ablation

• Hanke T et al. Circulation. 2009;120(11 Suppl):S177-84.

Selection of patients for redo ablation

- Pokushalov E et al. Circ Arrhythm Electrophysiol. 2011;4(6):823-31.
- Pokushalov E et al. Circ Arrhythm Electrophysiol. 2013;6(4):754-60.

Post atrial flutter ablation

• Mittal S et al Heart Rhythm. 2013. doi: 10.1016/j.hrthm.2013.07.044.

Primary stroke prevention (high risk of stroke)

Reveal AF study (enrolling)

